Literature DB >> 25421961

Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.

David J Mastropietro1, Hossein Omidian.   

Abstract

INTRODUCTION: Increased misuse and abuse of prescription pain medications has driven extensive research and development to produce what are best known as abuse-deterrent formulations (ADFs). The ADFs are intended to prevent, impede or discourage physical and chemical tampering while still being able to provide safe and accurate delivery of an abusable medication for therapeutic benefit. AREAS COVERED: This review primarily focuses on patents and company literature regarding the formulations, manufacturing and physiochemical properties of abuse-deterrent compositions. Also included are journal articles with relevance to the development of these novel technologies. Particular attention is given to oral dosage forms with applications found in prescription drug products, over-the-counter medications and proprietary technologies in development. Overall, the formulations of 14 drug products, 2 meth-resistant cold products and 17 pharmaceutical proprietary technologies are explored in detail. EXPERT OPINION: Despite the introduction of a wide range of formulation and technology interventions with different deterrence potential, the progression of these technologies seems to be moving from inhibiting only one type of abuse to stopping multiple types of tampering methods. Information on inherent strengths and weaknesses of various formulations can be utilized in the development of more robust and resistant ADF in the future.

Entities:  

Keywords:  abuse deterrent; misuse; nonmedical use; opioids; prescription drug abuse; tamper resistant

Mesh:

Substances:

Year:  2014        PMID: 25421961     DOI: 10.1517/14656566.2014.970175

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

Review 1.  Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Carmen Walter; Claudia Knothe; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

2.  Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Authors:  C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-31       Impact factor: 4.530

3.  Risk based in vitro performance assessment of extended release abuse deterrent formulations.

Authors:  Xiaoming Xu; Abhay Gupta; Manar Al-Ghabeish; Silvia N Calderon; Mansoor A Khan
Journal:  Int J Pharm       Date:  2016-01-16       Impact factor: 5.875

Review 4.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 5.  Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.

Authors:  Nalini Vadivelu; Daniel Chang; Leandro Lumermann; Thomas Suchy; Matthew M Burg; Manuel L Fontes
Journal:  Curr Pain Headache Rep       Date:  2017-02

6.  Effect of Manufacturing Process on the Retention of Abuse-Deterrent Properties of PEO-Matrix Tablets.

Authors:  Leyla Rezaei; Saikishore Meruva; Maureen D Donovan
Journal:  AAPS PharmSciTech       Date:  2021-12-27       Impact factor: 3.246

7.  The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Authors:  P M Coplan; H D Chilcoat; S F Butler; E M Sellers; A Kadakia; V Harikrishnan; J D Haddox; R C Dart
Journal:  Clin Pharmacol Ther       Date:  2016-06-22       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.